SCHEMBL23488191

SCHEMBL23488191

CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1OC(=O)c1cc(Cl)c(OCc2cccc(CNC(=O)[C@@H](N)CC(C)C)c2)c(Cl)c1C

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 7/20 0.39
LGALS1 P09382 2/20 0.39
LGALS7; LGALS7B P47929 2/20 0.39
LGALS9 O00182 1/20 0.39
LGALS4 P56470 4/20 0.35
LGALS8 O00214 3/20 0.34
OPRM1 P35372 2/20 0.33
OPRD1 P41143 2/20 0.33
OPRK1 P41145 1/20 0.33
POLB P06746 1/20 0.31
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488650 0.92 LGALS3 (0.39) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488649 0.88 LGALS3 (0.38) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488203 0.88 REN (0.37) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488212 0.88 LGALS3 (0.39) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488321 0.87 LGALS3 (0.35) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488538 0.85 LGALS3 (0.41) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488524 0.84 LGALS3 (0.44) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488217 0.83 LGALS3 (0.39) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488287 0.83 LGALS3 (0.47) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4
SCHEMBL23488619 0.83 LGALS3 (0.47) LGALS3LGALS1LGALS7; LGALS7BLGALS9LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 LGALS3 156/4885LGALS1 50/4885LGALS7; LGALS7B 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.